TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Bothersomeness of BPH symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prothrombin fragment 1 + 2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Thrombin-antithrombin complex levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of postoperative haemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of postoperative bleeding needing surgical intervention
Endpoint domain: Adverse events/effects
Primary endpoint: change in hemoglobin from baseline to days 60 and 90
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean serum ferritin at day 90
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean AVM volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Rankin Scale scores after surgery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: remission of colitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ankle joint function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development rate of exactly two follicles >=14 mm in diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Cancellation rate for overstimulation (more than three follicles >=14 mm in diameter)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in serum IL-2 and sIL-2R levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of CD3, CD4 and CD4/CD8 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement of clinical symptoms and quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: absolute change in snoring rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LS mean increase in trough FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Risk of cataract
Endpoint domain: Mortality/survival
Primary endpoint: Risk of visually significant AMD
Endpoint domain: Mortality/survival
Primary endpoint: Proportions of IgA-secreting cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportions of IgM-secreting cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportions of CD19(+)CD27(+) B cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: range of passive ductions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in cardiovascular profile between Monday and non-Monday values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart failure hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Disability pension receipt
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Total health care utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Accumulated weeks of unemployment and sickness benefit
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: serum concentrations of vitamin C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum concentrations of carotenoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in central aortic diastolic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in central aortic systolic pressure (CASP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mortality rate 30 days after ablation
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of appropriate ICD therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cement leakage
Endpoint domain: Adverse events/effects
Primary endpoint: Tube insertions per tube day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Abdominal radiographs per tube day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: illness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean degree of improvement in submental profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of rescue medication taken
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain measurement responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: undetectable total IgA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity for EmA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median IgA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ambulatory blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of hair shafts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematoma volume increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of death or dependency
Endpoint domain: Mortality/survival
Primary endpoint: mean comfort score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Arterial compliance (C2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Median Bishop score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exercise tidal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MethyleneTHF and THF concentrations in mucosa and tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RAND-36 energy score
Endpoint domain: Life impact
Endpoint subdomain: Energy
Primary endpoint: RAND-36 physical functioning score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: oral health-related quality of life scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of sufficient vestibule-palatal diffusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postintervention STI or UP
Endpoint domain: Adverse events/effects
Primary endpoint: CLDN18.2 expression prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exercise minutes per week change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fruit and vegetable servings per day change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival recession (REC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and duration of life-threatening thrombocytopenia
Endpoint domain: Adverse events/effects
Primary endpoint: target lesion revascularization-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in the amount of contrast media used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in operator radiation exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased diagnostic confidence in the exclusion of portal vein thrombosis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 6-month pregnancy rate
Endpoint domain: Mortality/survival
Primary endpoint: Somatic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RAPID3 remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MSC Revealing Competence scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Quality of Life (QOLIE-31 scores)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adverse Effect Profile (AEP scores)
Endpoint domain: Adverse events/effects
Primary endpoint: Ratio of saturated to monounsaturated fatty acids of skin surface triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acne lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tuberculosis rates (cases per 100 person-years)
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality (number of deaths during follow-up)
Endpoint domain: Mortality/survival
Primary endpoint: Anti-polyribosylribitol phosphate antibody titers after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR20 response rate at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occupationally significant fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Days with low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of death or neurodevelopmental delay
Endpoint domain: Mortality/survival
Primary endpoint: Mean absolute difference between examination methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for endotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall intubation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Obstetric anal sphincter injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline forced expiratory volume in 1s (FEV(1))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline carbon monoxide diffusing capacity (DL(CO))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Schirmer 1 test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FCT (Fluorescein Clearance Time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: power output at respiratory compensation point
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: anaerobic working capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: good physical functioning trajectory
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: oxidation resistance of LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: BPI average pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of B-cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hospitalization-related medical expenditures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: ddI C(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertical range of motion improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of radiation retinopathy
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with significant graft problems requiring major revision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Quality of visualization of grafts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laboratory values normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High-density lipoprotein cholesterol (HDL) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient survival at 4 years
Endpoint domain: Mortality/survival
Primary endpoint: Graft survival at 4 years
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of cognitive impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MoCA scale total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced sexual aversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality associated with vitamin A supplementation
Endpoint domain: Mortality/survival
Primary endpoint: Frequency and intensity of climacteric symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month cessation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viability of isolated adipocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of adipose tissue samples obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trauma level of the biopsy procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total motor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gross motor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensory sensitivity behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean time to C(max) (t(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of neonatal anemia (hematocrit <45%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean venous hematocrit values at 6 hours of life
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: hypnotic endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: analgesic endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in skin pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Acceptability of BATHE
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Benefits of person-centred consultations
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: β‐CTX concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: satisfactory relief of general symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: reduction in abdominal bloating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: reduction in abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: need for rescue drugs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of predicted forced expiratory volume in 1 second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FJV serving difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Anesthetic effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-related quality of life (QALY)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mean functional disability scores during migraine attacks
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: weight satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: skin capillary reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: nontechnical skills performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma DNPH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UTI rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: levels of cys‐LTs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in buprenorphine SL tablet consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of pain-free sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Central Systolic Blood Pressure (CSBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: prevention of excessive weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resistance to displacement values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain-free status at 2 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Photophobia reduction at 2 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative symptoms ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RBC folate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Worsening of symptoms on the FTD Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in binging and compensatory behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate antihypertensive effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse drug effects
Endpoint domain: Adverse events/effects
Primary endpoint: myeloperoxidase levels in bronchoalveolar lavage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mast cell immunoreactivity for tryptase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Comfort in daily activities
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of ethanol beverages chosen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective effects of ethanol
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: No bleeding or spotting in the previous 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary GSV occlusion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: motion sickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abnormal high stimulating rate ABR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinically significant changes in hematologic and biochemical blood tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean maximum plasma XC8 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: participation rates for chlamydia screening
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Foot Function Index sum score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent days abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of bleeding intraoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for transfusions of blood and blood products
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: theatre time to achieve haemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Frequency of inadequate analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30% decrease in stool weight defined response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: diagnostic accuracy on near-transfer cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UDI-6 and OAB-q scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Remission rate after 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained remission at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease activity at 48 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nonattendance rate
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Purchase of contact lenses
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Facial lipoatrophy scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predicted probability of admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with insoles
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: median sedation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum fall in systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: etco2 increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to normal domestic activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: recidivation rate
Endpoint domain: Mortality/survival